There has been an increase in interest in the use of altered peptides as antigen-specific therapeutic agents in autoimmune diseases. Here we investigated the inhibitory effect and possible mechanism of an altered influenza virus haemagglutinin (HA)-derived peptide in collagen-induced arthritis (CIA). CIA was induced in DBA/1 mice by immunisation with type II collagen (CII). Altered HA308-317, wild-type HA308-317 or irrelevant peptide was administered intranasally beginning from arthritis onset. Clinical and histological scores were assessed, and cytokine levels in the serum or supernatants from splenocytes were determined. The percentages of Th1 and Th2 cells in response to different peptides were analysed by FACS both in vivo and in vitro. Our results showed that intranasal administration of altered HA308-317 peptide significantly ameliorated CIA. The therapeutic effect of altered HA308-317 peptide was associated with a substantial decrease in production of interferon (IFN)-c, interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, anti-CII IgG, IgG1 and IgG2a antibodies, and an markedly increase in production of IL-10 and IL-4 in serum or supernatants from splenocytes treated with altered HA308-317 peptide. The percentage of Th2 (CD4 1 IL-4 1 ) cells was upregulated significantly by altered HA308-317 peptide with a decreased percentage of Th1 (T helper 1; CD4 1 INF-c 1 ) cells both in vivo and in vitro. These findings suggest that altered HA308-317 peptide might be a promising candidate for rheumatoid arthritis (RA) treatment.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease of the joints that often leads to cartilage and bone erosion. The drugs and agents currently used to treat RA remain unsatisfactory in preventing joint damage. Although some new strategies for treatment of RA have been introduced, including biological agents, they do not retard disease progression sufficiently in some patients. Meanwhile, they are expensive and have multiple effects. Therefore, it is necessary to develop effective therapeutic alternatives for RA to inhibit the inflammatory and autoimmune components of the disease without any adverse effects. 1 Although RA is a complex disease, with both genetic and environmental factors contributing to its etiology, many studies have indicated that the specific recognition and combination of antigenic peptide, HLA-DR1/4 and T-cell receptor (TCR) are involved in the initiation of RA. 2, 3 Type II collagen (CII) has been implicated as one of the most important autoantigens involved in RA pathogenesis. 4 CII256-271 peptide contains main antigenic epitopes which can trigger RA-specific T-cell response. 5 The influenza virus haemagglutinin (HA) 308-317 peptide (YVKQNTLKLA), which shares a similar three-dimensional structures to CII256-271, can bind HLA-DR1/4 molecules with higher affinity. 6 By crystallographic analysis and alanine scanning, it has been showed that 308Y, 311Q, 313T, 314L and 316L of HA306-318 are HLA-DR1/4 contact residues, while 309V, 310K, 312N and 315K are mainly responsible for binding with TCR. Since there has been an increase in interest in altered peptides which can be used as antigen-specific therapeutic agents in autoimmune diseases, [7] [8] [9] [10] [11] we designed a series of altered HA308-317 peptides with amino acid substitutions at TCR contact sites (YAKQATLALA) in previous in vitro studies. The results showed that these altered peptides inhibited T-cell proliferation stimulated by wild-type HA306-318 peptide or CII263-272 peptide in peripheral lymphocytes of RAand CII-specific T-cell clones. 12 However, the protective role and mechanism(s) of these altered HA peptides in collagen-induced arthritis (CIA) model has not been studied.
Autoimmune CD4 1 helper T cells are required for the initiation and progression of RA. Classically, CD4
1 T cells were considered to differentiate into two lineages, T helper 1 (Th1) cells or Th2 cells. 13 Th1 cells secrete interferon-c (IFN-c) and regulate cellular immunity. On the other hand, Th2 cells secrete interleukin (IL) -4, -5 and -13, which regulate humoral immunity. Some reports indicated that the Th2 cytokine profile predominates at the remission phase of CIA, and the Th1 cells are associated with the acute phase of the disease. 14, 15 RA has been believed to be a disease in which the Th1/Th2 balance is skewed to Th1. 16 And a lot of studies have proved that manipulation of the balance between Th1-and Th2-type cytokines will alter the outcome of CIA. [17] [18] [19] Additionally, Th1 and Th2 cells differentially directed T cell-independent IgM isotypes to IgG isotypes shift in activated B lymphocytes by inducing a switch to IgG2a and IgG1, respectively. The response of IgG2a has been supposed to be more relevant to CIA development than IgG1. 20, 21 In this study, we investigated whether altered HA peptide suppress disease by inhibition of T-cell proliferation and shifting of the immune response towards a Th2-type response.
MATERIALS AND METHODS

Peptide synthesis
The wild-type HA308-317 peptide (YVKQNTLKLA), altered HA306-318 peptide (YAKQATLALA) and irrelevant peptide (ALALTAQKAY) were synthesized by solid-phase techniques on an Applied Biosystems Peptide Synthesizer (SBS Gene Technology Company, Beijing, China). The peptides were purified by high-performance liquid chromatography with a purity of more than 95%.
Animals
Male DBA/1 mice, ages 6-8 weeks, were purchased from SLAC Laboratory Animal Center (Shanghai, China). They were housed under specific pathogen-free conditions and fed standard rodent chow and water ad libitum. The studies were approved by the Animal Care and Use Committee of Peking University People's Hospital.
Induction and clinical assessment of CIA For induction of arthritis, bovine CII (Chondrex, Redmond, WA, USA) was dissolved at 3 mg/ml in phosphate-buffered saline (PBS) containing 0.1 M acetic acid (at 4 uC overnight), and emulsified in an equal volume of complete Freund's adjuvant (Sigma-Aldrich, St Louis, MO, USA). Mice were immunized intradermally at the base of the tail with a total of 100 ml emulsion containing 150 mg CII. Three weeks later, the animals were boosted with an intradermal injection of 75 mg CII emulsified in incomplete Freund's adjuvant (SigmaAldrich). Mice were analysed by two independent observers, under blinded conditions at regular intervals and monitored for signs of arthritis using two clinical parameters, paw swelling and clinical score. Paw swelling was assessed by measuring the mean thickness of all paws with a micrometer caliper. Clinical score was assessed by using the following system: 0, normal; 1, mild inflammation (redness and swelling) of a single area (toes, midfoot or ankle); 2, mild to moderate inflammation of two areas (toes, midfoot or ankle); 3, moderate to severe inflammation involving entire paw; 4, severe inflammation of entire paw resulting in ankylosis and loss of joint movement. 22 Each limb was graded, giving a maximum possible score of 16 per animal. A mean arthritic score value was calculated. The day of the first immunisation was designated day 0.
Peptide treatment protocols Treatment commenced after onset of CIA (proximately day 26), when arthritis had become well established (arthritis score .2). All sick mice were randomly divided into four groups with 10 mice each group. In each group, 25 mg of altered HA peptide, wild-type HA peptide or irrelevant peptide dissolved in PBS or PBS alone (control) was intranasally administered, respectively (a total volume of 10 ml, with 5 ml per nostril, peptide concentration 2.5 mg/ml). Peptides were given daily until day 53 after primary immunisation.
Histopathological analysis of arthritis
All four paws from each mouse were collected at day 53 after primary immunisation. The paws were fixed, decalcified, paraffin-embedded, sectioned (4 mm) and stained with haematoxylin and eosin. Sections were analysed microscopically by two observers in a blinded manner for the degree of inflammation and for cartilage and bone destruction according to the method reported previously, 23 using the following scale: 0, normal synovium; 1, synovial membrane hypertrophy and cell infiltrates; 2, pannus and cartilage erosion; 3, major erosion of cartilage and subchondral bone; and 4, loss of joint integrity and ankylosis. 
Flow cytometric analysis
The splenocytes were obtained by mechanical shredding and resuspended in 10% fetal bovine serum RPMI 1640 medium at the end of the experiments. For intracellular cytokine analysis, cells were stimulated with phorbol myristate acetate (PMA, 50 ng/ml; Sigma-Aldrich) plus ionomycin (500 ng/ml, Sigma-Aldrich) for 4-5 h in the presence of Brefeldin A (1 : 10 dilution; BD Biosciences, San Jose, CA, USA). Then, cells were stained with FITC-conjugated anti-CD4 monoclonal antibody (BD PharMingen, San Diego, CA, USA), fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences), followed by intracytoplasmic staining using one of the following fluorescently labelled antibodies: phycoerythrin-conjugated anti-IFN-c or anti-IL-4 mAb (BD PharMingen). Isotype-matched antibodies were used as controls, and IgG block (Sigma-Aldrich) was used to avoid nonspecific binding to Fc receptors. Percentage and the absolute number of positive stained cells were analysed on a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson, San Diego, CA, USA).
Measurement of serum anti-CII antibody IgG and its subtypes by ELISA Serum samples were collected at the end of the experiment (day 53) for determination of IgG, IgG1 and IgG2a antibodies level with three commercially available test kits (Mice IgG, IgG1 and IgG2a Anti-type II Collagen Antibody Assay Kits; Chondrex, Redmond, WA, USA). Take IgG for example, eight-well strips coated with CII were mixed with mice serum samples to allow specific binding of anti-CII antibodies. The secondary antibody (peroxidase-conjugated goat antimice IgG) was added and then the peroxidase was added to react with orthophenylenediamine and urea H 2 O 2 . Antibody levels were quantified using seven standard serum (0.25-16 units/l). The tested sera were diluted so that the measured o.d. values were between standard serum 1 and 6. Values presented in this plate are calculated by multiplying the serum dilution with the measured antibody level.
dioxide for 1 h to remove adherent cells. The adherent cell fraction mainly consisting of macrophages were termed antigen-presenting cells. Subsequently, CD4
1 T cells were purified from the non-adherent cell fraction using the mouse CD4 1 T Cell Isolation Kit (Miltenyi Biotec, Bergich Gladbach, Germany) according to the manufacturer's instructions. The purity of CD4 1 T cells was over 97%. For proliferation assay, 2.5310 5 purified CD4 1 T cells were cultured for 4 days in the presence of 1310 5 irradiated (3000 rad) splenic antigen-presenting cells per well in triplicate in 96-well plates (Costar, Cambridge, CA, USA) and stimulated with altered HA peptide, wild-type HA peptide or irrelevant peptide at a final concentration of 50 mg/ml. ConA (2 mg/ml) was used as positive control. Cells were incubated at 37 uC in 5% CO 2 for 4 days. Before the last 16 h of culture, 1 mCi of 3 H-thymidine was added to each well. The cells were then harvested, and the incorporated radioactivity was counted in a b-scintillation counter. The secretion of supernatants IFN-c, IL-4 and IL-10 by CD4
1 T cells after 3 days of peptides stimulation in vitro was determined by ELISA as described previously. The frequencies of Th1 and Th2 cells were determined by flow cytometric analysis as described above.
Statistical analysis
Data analyses were performed using SPSS version 16.0 software package (SPSS Inc., Chicago, IL, USA). Results were expressed as mean6s.d. Statistical differences were analysed using Student's t-test or one-way analysis of variance. P values less than 0.05 were considered statistically significant.
RESULTS
Decreased severity of CIA following treatment with altered HA peptide The mice treated with irrelevant peptide or PBS control showed serious clinical signs of disease, such as redness and/or swelling of the paws. The arthritis score and the extent of paw swelling in CIA mice treated with irrelevant peptide had no difference with those in CIA mice without any peptide treatment (PBS control) (P.0.05). Therefore, irrelevant peptide did not show any protective effect on CIA progression. Notably, mice treated with altered HA peptide showed decreased severity of CIA in comparison with irrelevant peptide-treated arthritic mice (Figure 1a) , as assessed by clinical score and paw swelling. As shown in Figure 1b , administration of altered HA peptide had significantly reductions of the arthritis score compared with irrelevant peptide starting on day 32 until day 53 when mice were killed. At day 53, the mean arthritis score in altered HA peptidetreated CIA mice (2.6060.50) was much lower than that in irrelevant peptide-treated mice (7.7060.78; P,0.01). Meanwhile, the extent of paw swelling was significantly decreased in altered HA peptide-treated mice (2.1960.12) as compared with that observed in irrelevant peptide-treated mice (2.9860.08; P,0.01) (Figure 1c) . Interestingly, treatment with wild-type HA peptide also resulted in a reduction of clinical score (5.1060.81) and the extent of paw swelling (2.5560.12) compared with irrelevant peptide (P,0.05). However, altered HA peptide offered much better protection against CIA compared with wild-type HA peptide (P,0.05).
Inhibitory effects of altered HA peptides on histopathological changes of CIA mice The therapeutic effect of altered HA peptide on CIA mice was further verified by histological examination. CIA mice treated with irrelevant peptide developed CIA-characteristic chronic inflammation of synovial tissue, pannus formation, cartilage destruction and bone erosion (Figure 2a ). In contrast, there was a remarkable reduction in inflammatory infiltration and pannus formation within the joint space after altered HA peptide therapy. Cartilage destruction and bone erosion were significantly ameliorated (Figure 2c ). Consistent with clinical observations, the average histological score was markedly lower in altered HA peptide-treated CIA mice (0.5560.20) compared with irrelevant peptide-treated CIA mice (2.0260.40; P,0.01) (Figure 2d ). In wild-type HA peptide-treated mice, milder synoviocyte hyperplasia and articular cartilage erosion were noted (Figure 2b) , and the degree of arthritis (histological score: 1.2560.20) was significantly reduced compared with irrelevant peptide-treated mice (P,0.01) (Figure 2d ). However, altered HA peptide showed much stronger effects compared with wild-type HA peptide (P,0.01).
Effect of altered HA peptide treatment on serum cytokine production We investigated the effect of different peptides on the production of inflammation mediators that are mechanistically linked to the severity of CIA. After the experiments, serum was collected for the detection of IL-10, IL-4, IL-6 and MCP-1 secretion. Strikingly, serum IL-10 (70.24625.58 pg/ml) and IL-4 (47.90625.58 pg/ml) levels in altered HA peptide-treated mice were substantially elevated, compared with those detected in wild-type HA peptide-treated (14.5062.91 and 22.8065.14 pg/ml, respectively; P,0.01) or irrelevant peptide-treated mice (6.5362.42 and 8.4562.35 pg/ml, respectively; P,0.01) (Figure 3a and b) . No difference was observed in the levels of serum IL-10 between irrelevant peptide and wild-type HA peptide-treated group (Figure 3a ). In addition, as shown in Figure 3c (Figure 4b ), compared with irrelevant peptide (P,0.01). However, the effect was much milder than altered HA peptide (P,0.01).
Effect of altered HA peptide on anti-CII antibodies production Besides T-cell immunity, we examined whether altered HA peptide affected antigen-specific B-cell responses. We measured the serum levels of total IgG or isotype-specific IgG2a and IgG1 anti-CII antibodies after treatment with different peptides. As shown in Figure 5 , treatment of CIA mice with irrelevant peptide resulted in high levels of CII-specific IgG (229.37616.98 mg/ml) (Figure 5a ), IgG1 (59.7263.24 mg/ml) The arthritis score in mice treated with irrelevant peptide had no difference from that in mice without any peptide treatment (PBS control) (P.0.05). The arthritis score in mice treated with altered HA peptide was much lower compared with that in mice treated with irrelevant peptide from day 32 (P,0.05). Additionally, the arthritis score in mice treated with wild-type HA peptide was lower compared with that in mice treated with irrelevant peptide beginning on day 41 (P,0.05), but higher than that in mice treated with altered HA peptide from day 41 (P,0.01). (c) The paw thickness in mice treated with irrelevant peptide had no difference with that in mice without any peptide treatment (PBS control) (P.0.05). The paw thickness in mice treated with altered HA peptide was much lower compared with mice treated with irrelevant peptide from day 32 (P,0.05). And the paw thickness in mice treated with wild-type HA peptide was lower compared with that in mice treated with irrelevant peptide from day 41 (P,0.01), but higher than that in mice treated with altered HA peptide from day 35 (P,0.05). Results are expressed as mean6s.d. from three separate experiments (10 mice/group/experiment). Compared with irrelevant peptide, *P,0.05, **P,0.01; compared with wild-type HA peptide, D P,0.05, DD P,0.01. CIA, collagen-induced arthritis; HA, haemagglutinin; PBS, phosphate-buffered saline. In addition, as shown in Figure 6b , altered HA peptide led to a significant reduction in supernatant IFN-c (80.18617.02 pg/ml) production by T cells compared with wild-type HA peptide (213.566 39.71 pg/ml; P,0.01) and irrelevant peptide (166.16624.80 pg/ml; P,0.01), whereas the production of cytokines IL-4 (142.02625.91 pg/ ml) and IL-10 (219.68663.39 pg/ml) was increased by altered HA peptide compared with wild-type HA peptide (26.2965.53 and 71.56615.53 pg/ml, respectively; P,0.01) and irrelevant peptide (54.7368.75 and 76.16618.23 pg/ml, respectively; P,0.01). In contrast, wild-type HA peptide upregulated the production of IFN-c (P,0.01), decreased the production of IL-4 (P,0.01) and had no effect on IL-10 (P.0.05) compared with irrelevant peptide.
Next we determined the frequency of Th1 and Th2 cells on sorted CD4 1 T cells. As shown in Figure 6c , Altered HA peptide decreased the frequency of Th1 cells (5.4260.82%) compared with wild-type HA peptide (13.0861.08%; P,0.01) and irrelevant peptide (8.7960.90%; P,0.01). The results suggested that altered HA peptide partially inhibited the differentiation of autoreactive/inflammatory Th1 cells, a finding that was in accordance with the results of the production of IFN-c in supernatants. In addition, the frequency of Th2 cells (10.556 1.39%) was upregulated in isolated CD4
1 T cells stimulated with altered HA peptide in vitro compared with irrelevant peptide (8.6761.07%; P,0.05) and wild-type HA peptide (4.5261.32%; P,0.01). However, wild-type HA peptide decreased the frequency of Th2 and increased Th1 subsets in vitro compared with irrelevant peptide (P,0.01) (Figure 6c ).
DISCUSSION
This is the first study to elucidate the effects of altered HA peptide therapy in CIA mice, both in vivo and in vitro. There are several new findings with some major implications. First of all, we designed and synthesized an altered HA peptide by solid-phase techniques, which is an effective therapy of CIA. It not only reduced visual clinical scoring and the extent of paw swelling, but also suppressed histopathological changes on the joints of CIA mice. In addition, protection conferred by altered HA peptide was mediated by suppressed proliferation of CIIspecific CD4
1 T cells and immune deviation in their response towards Th2-type cytokine production. And a marked reduction of anti-CII IgG2a circulating levels was also observed in our study.
Altered HA peptide strongly inhibited inflammatory response by downregulating the production of proinflammatory cytokine IL-6 and chemokine MCP-1. High levels of IL-6 are commonly found in blood and joints during RA. 24 Chemokines are responsible for the infiltration into the joint and activation of various lymphocyte populations, which play important roles in the development of CIA. 25, 26 The ability of altered HA peptide to manipulate several mediators of inflammation might provide a therapeutic advantage over neutralizing antibodies and receptor antagonists that only targeted a single cytokine. CD4 1 T cells have been traditionally divided into the Th1 and Th2 subsets, based on whether they secrete IFN-c or IL-4, respectively. 13, 27 Th1 cells release proinflammatory cytokines, chemokines and free (9.5762 radicals, infiltrate the synovium, and promote macrophage and neutrophil activation, which together mediate inflammatory reaction and immunological injury. 28 In contrast, Th2 cells offer beneficial effects on CIA development. 14, 15 Therefore, the therapeutic methods that promote Th2 response and inhibit Th1 response are beneficial for arthritis. Here our results show that intranasal treatment with altered HA peptide led to the significant inhibition of IFN-c, and increase in IL-4 and IL-10 production, which implied a shift from Th1 to Th2 response. Wild-type HA peptide also exerted such functions, but altered HA peptide even had stronger inhibitory effects than wild-type HA peptide. However, the effects of altered HA peptide and wild-type HA peptide on T-cell activation are opposite in vitro. CII-primed T-cell proliferation treated with altered HA peptide in vitro was suppressed, compared with those with wild-type HA peptide treatment. Furthermore, in consistent with the findings in vivo, altered HA peptide also displayed striking immunomodulating effects on the priming of CD4 1 T cells in vitro. It resulted in the skewing of activated CD4 1 T cells towards lower proportion of Th1 cells but increased frequency of Th2 cells, as well as increased levels of anti-inflammatory and regulatory cytokines IL-4 and IL-10. In contrast, wild-type HA peptide had opposite effects on the priming of CD4 1 T cells in vitro compared with its role in vivo. It increased Th1 and decreased Th2 populations. Thus, it indicated that altered HA308-317 peptides with substitutions of TCR contact residues are low T-cell stimulators and are able to competitively inhibit arthritic T-cell activation and selectively promote Th2 differentiation in vitro.
In addition, anti-CII IgG levels have been reported to be responsible for the disease activity of RA, especially in the acute phases of the disease. The increase of serum anti-CII IgG levels in arthritis is associated with acute phase reactants and the several proinflammatory cytokines, e.g., tumor-necrosis factor-a and IL-6. 29, 30 Meanwhile, the subtypes of IgG are associated with Th1/Th2 responses. More specifically, IgG2a is mediated by antigen-specific Th1 responses and IgG1 is associated with Th2 responses. 31, 32 Some reports implied that suppression of CIA accompanies reduction of the CII-specific IgG2a response. 33, 34 However, it should be stressed that there are also reports showing that both anti-CII-specific IgG1 and IgG2a antibodies were highly arthritogenic. 35 Our study indicated that altered HA peptide reduced the production of serum anti-CII-specific IgG, IgG1 and IgG2a levels, especially the IgG2a/ IgG1 ratio, which implied altered HA peptide as one of the important factors to suppress the progression of arthritis by blocking the inflammatory and autoimmune components of CIA.
In conclusion, the intranasal treatment with altered HA peptide could ameliorate CIA by inducing Th2 cells and suppressing the development of Th1 cells. And we did not notice any adverse effects of altered HA peptide through our present experiment. Thus, altered HA peptide 308-317 could be a promising candidate for treatment of RA and other autoimmune diseases. The capacity of altered HA peptide to ameliorate ongoing disease also fulfills an essential prerequisite for an antiarthritic agent, as treatment is started after the onset of the disease. At the moment, we are not able to understand thoroughly the precise mechanism by which altered HA peptide exerts its therapeutic effects. So we plan to further study whether there are other important mechanisms involved in the pathogenesis of CIA, such as transcription of indoleamine 2,3-dioxygenase, novel Treg-IL-9-mast cell pathways, 36 local catabolism of the amino acid tryptophan 37 and the pathogenic Th17 lineage, 38 a new subset of IL-17-producing Th cells distinct from Th1 and Th2 cells.
